INTRODUCTION AND OBJECTIVES: Immune-related adverse events (irAEs) develop in some patients with metastatic renal cell carcinoma (mRCC) on immune checkpoint inhibitor therapy. The association of irAEs with prognosis has been reported in melanoma and non-small cell lung cancer, but remains unclear in mRCC. This study aimed to evaluate the association of irAEs with prognosis in patients with mRCC treated with nivolumab.
METHODS: We retrospectively evaluated 47 mRCC patients treated with nivolumab following systematic therapy. The irAEs involved the liver, kidney, pancreas, and skin, and endocrine, pulmonary, and gastrointestinal systems, with grading based on the CTCAE v4.0. Progression-free survival (PFS) and overall survival (OS) after nivolumab initiation were compared according to irAE development.
RESULTS: irAEs developed in 23 patients (48.9%). Median time from therapy initiation to irAE development was 1.38 months. Rash/pruritus was the most frequent event (n[11, 23.4%) . irAEs with grade !3 were observed in 9 patients (19.1%). PFS and OS were significantly longer in patients with irAEs than in those without irAEs (median 2 year-PFS: 44% vs. CONCLUSIONS: This retrospective study showed that patients with irAEs had favorable outcomes after nivolumab therapy. The data showed that irAE development might be an effective surrogate marker of patient survival on nivolumab.
Source of Funding: None.
PD03-09 SAFETY AND FEASIBILITY OF NEPHRECTOMY AFTER RECEIPT OF IMMUNE CHECKPOINT INHIBITORS FOR RENAL CELL CARCINOMA
Nirmish Singla*, Roy Elias, Rashed Ghandour, Yuval Freifeld, Isaac Bowman, Solomon Woldu, Jeffrey Gahan, Aditya Bagrodia, James Brugarolas, Hans Hammers, Vitaly Margulis, Dallas, TX INTRODUCTION AND OBJECTIVES: With the approval of immune checkpoint inhibitors (ICI) for metastatic renal cell carcinoma (RCC), the role, timing, and safety of surgically excising the primary tumor remain unclear. We sought to evaluate the safety and feasibility of nephrectomy following receipt of ICI for RCC.
METHODS: We reviewed our experience of RCC patients who underwent nephrectomy from 2016e2018 following exposure to nivolumab or combination ipilimumab/nivolumab. Demographics, IMDC risk score, and pathology were collected. Surgical outcomes including operative time (OT), estimated blood loss (EBL), hospital length of stay (LOS), readmission rates, and 30-and 90-day complication rates were analyzed using descriptive statistics.
RESULTS: 11 nephrectomies (10 radical, 1 partial) were performed in 10 patients after ICI with median postoperative followup 98 days. 6 patients received 1-4 cycles of ipilimumab/nivolumab, while 5 received 2-12 infusions of nivolumab preoperatively. One patient with non-metastatic, synchronous bilateral renal masses underwent staged left radical nephrectomy and right partial nephrectomy. 5 surgeries were performed laparoscopically, and 4 patients underwent thrombectomy. IMDC score for metastatic patients was intermediate (7/9) or poor (2/9). One patient exhibited complete response (pT0) to ICI, and 3/4 patients who underwent metastasectomy for hepatic, pulmonary, or adrenal lesions exhibited no malignancy in any of the metastases resected. No patients experienced any major intraoperative complications, and all surgical margins were negative. Median OT, EBL, and LOS were 180 minutes, 100 mL, and 4 days, respectively. One patient died of progressive disease >3 months after surgery; one patient required thoracentesis and another required paracentesis of a sterile fluid collection in the hepatic resection bed. No complications were noted in the remaining 7 patients, none of whom required readmission.
CONCLUSIONS: Nephrectomy following ICI for RCC is safe and technically feasible with favorable surgical outcomes and pathologic response. As multimodal management in the era of ICI continues to evolve, use of neoadjuvant ICI for selected patients may warrant attention.
Source of Funding: none

PD03-10 COMPREHENSIVE MOLECULAR AND GENOMIC CHARACTERIZATION OF PANCREATIC TROPISM IN METASTATIC RENAL CELL CARCINOMA
INTRODUCTION AND OBJECTIVES:
Patients with metastatic renal cell carcinoma (mRCC) involving the pancreas have been shown to exhibit a relatively indolent course, yet the biologic explanation is unclear. We sought to characterize the genomic landscape of patients with mRCC harboring pancreatic metastases (PM) to identify molecular drivers of pancreatic tropism.
METHODS: mRCC patients harboring PM from UTSW and Cleveland Clinic were identified. Clinicopathologic data and oncologic outcomes were analyzed. Samples were obtained from primary tumors, metastatic sites (including pancreatic or other distant Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e71
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